Current News Articles
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim Therapeutics for the Treatment of Autoimmune Diseases
Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, has entered i...
Click to Read Full Article
New method sees multiple uses including replacing metal in cars and airplanes, wind turbines, battery manufacturing, and construction
New pilot fund supports Canada's most promising early-stage cleantech entrepreneurs.
Makena Resources Inc. Announces Increase to Previously Announced Private Placement, Strategic Investment and Update of Business Combination with BioCan Technologies Inc., and Epimeron Inc., to form Willow Biosciences Inc.
Makena increases the size of its previously announced private placement of common shares and units from $15 million to $28.5 million, including an investment of $12 million units by Tuatara Capital. ...